Education
About Us
Working with TipRanks
Follow Us
Abbisko Cayman Limited (HK:2256)
:2256
2256 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.56 - HK$6.94
Previous CloseN/A
Volume927.00K
Average Volume (3M)4.15M
Market Cap
HK$4.67B
Enterprise Value-HK$130.16M
Total Cash (Recent Filing)-¥297.06M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)142.8
Beta1.07
Next Earnings
Aug 19, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding679,605,350
10 Day Avg. Volume7,793,871
30 Day Avg. Volume4,145,541
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.00Price Target Upside162.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Abbisko Cayman Limited News
PremiumCompany Announcements
Abbisko Cayman Founder Increases Stake, Signaling Confidence in Growth
PremiumCompany Announcements
Abbisko Cayman Limited Announces Board Structure and Committee Roles
PremiumCompany Announcements
Abbisko Cayman Limited Announces HKD200 Million Share Repurchase Plan
PremiumCompany Announcements
Abbisko Cayman Limited Announces Board and Committee Changes
PremiumCompany Announcements
Abbisko Cayman Limited Announces Board Composition and Committee RolesPremiumCompany Announcements
Abbisko Cayman Limited Schedules Board Meeting to Review 2024 Financials---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe MANEUVER trial demonstrated a 54% ORR in patients treated with pimicotinib compared to 3.2% for patients treated with placebo.
Financial PerformanceThe analyst's price target for Abbisko Therapeutics stock has been raised from HK$16.00 to HK$18.00.
Partnerships And LicensingMerck KGaA exclusively licensed commercialization rights for the asset in mainland China, Hong Kong, Macau, and Taiwan, with options for global rights.
Bears Say
Trial UncertaintiesThe global Phase 3 trial for CSF-1R inhibitor pimicotinib (ABSK021) in TGCT completed enrollment, with potential results by YE24/1Q25.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.97% Mutual Funds
― Other Institutional Investors
99.00% Public Companies and
Individual Investors
2256 FAQ
What was Abbisko Cayman Limited’s price range in the past 12 months?
Abbisko Cayman Limited lowest stock price was HK$2.56 and its highest was HK$6.94 in the past 12 months.
What is Abbisko Cayman Limited’s market cap?
Abbisko Cayman Limited’s market cap is HK$4.67B.
When is Abbisko Cayman Limited’s upcoming earnings report date?
Abbisko Cayman Limited’s upcoming earnings report date is Aug 19, 2025 which is in 164 days.
How were Abbisko Cayman Limited’s earnings last quarter?
Abbisko Cayman Limited released its earnings results on Mar 03, 2025. The company reported -HK$0.3 earnings per share for the quarter, beating the consensus estimate of -HK$0.417 by HK$0.118.
Is Abbisko Cayman Limited overvalued?
According to Wall Street analysts Abbisko Cayman Limited’s price is currently Undervalued.
Does Abbisko Cayman Limited pay dividends?
Abbisko Cayman Limited does not currently pay dividends.
What is Abbisko Cayman Limited’s EPS estimate?
Abbisko Cayman Limited’s EPS estimate is -0.42.
How many shares outstanding does Abbisko Cayman Limited have?
Abbisko Cayman Limited has 679,605,350 shares outstanding.
What happened to Abbisko Cayman Limited’s price movement after its last earnings report?
Abbisko Cayman Limited reported an EPS of -HK$0.3 in its last earnings report, beating expectations of -HK$0.417. Following the earnings report the stock price went up 4.809%.
Which hedge fund is a major shareholder of Abbisko Cayman Limited?
Currently, no hedge funds are holding shares in HK:2256
---
Abbisko Cayman Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$18.00 (162.01% Upside)
HK$18.00 (162.01% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
154.44%
12-Months-Change
Fundamentals
Return on Equity
1.43%
Trailing 12-Months
Asset Growth
-3.72%
Trailing 12-Months
Company Description
Abbisko Cayman Limited
Abbisko Cayman Ltd is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies.
---
2256 Stock 12 Month Forecast
Average Price Target
HK$18.00
▲(162.01% Upside)
Technical Analysis
Zai Lab Ltd
―
Peijia Medical Ltd.
―
Akeso, Inc.
―
Viva Biotech Holdings
―
MicroPort CardioFlow Medtech Corp.
―
Best Analysts Covering 2256
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+87.83%
reiterated a buy rating 4 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +87.83% per trade.
---